COPD - Deutsche Gesellschaft für Pneumologie

Leitlinie
e33
" Herr Prof. Dr. Claus Vogelmeier
Universitätsklinikum, Schwerpunkt Pneumologie
Baldinger Str.
35033 Marburg
Deutsche Atemwegsliga
" Herr Karsten Wagner−Gillen
GlaxoSmith−Kline GmbH
Theresienhöhe 11
80 339 München
Arzneimittelhersteller
" Herr Prof. Dr. Tobias Welte
Med. Hochschule Hannover, Pneumologie
Carl−Neuberg−Str. 1
30 625 Hannover
Deutsche Atemwegsliga
" Herr Prof. Dr. Ralf Wettengel
Schillbachstr. 13
07743 Jena
Deutsche Atemwegsliga
" Herr Prof. Dr. Heinrich Worth
Med.Klinik I/Klinikum Fürth
Jakob−Henle−Str. 1
90766 Fürth
Deutsche Atemwegsliga
Literatur
1 Worth H, Buhl R, Cegla U et al. Leitlinie der Deutschen Atemwegsliga
und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und
Therapie von Patienten mit chronisch obstruktiver Bronchitis und
Lungenemphysem (COPD). Pneumologie 2002; 56: 704 ± 738
2 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global
strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease. Updated 2005 http://www.gold−
copd.com(goldwr2005.pdf,
3 Celli BR, MacNee W and committee members. Standards for the diag−
nosis and treatment of patients with COPD: a summary of the ATS/
ERS position paper. Eur Respir J 2004; 23: 932 ± 946
4 National Collaborating Centre for Chronic Conditions, National Institu−
te of Clinical Excellence (NICE). Chronic obstructive pulmonary disea−
se. National clinical guideline on management of chronic obstructive
pulmonary disease in adults in primary and secondary care. Thorax
2004; 59 Suppl 1: 1 ± 232
5 Pauwels RA, Buist AS, Calverley PMA et al. Global strategy for the di−
agnosis, management, and prevention of chronic obstructive pulmo−
nary disease. Am J Respir Crit Care Med 2001; 163: 1256 ± 1276
6 ATS Statement. Standards for the diagnosis and care of patients with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med
1995; 152: S77± S120
7 Siafakas NM, Vermeire P, Pride NB et al. ERS−Consensus statement.
Optimal assessment and management of chronic obstructive pulmo−
nary disease. Eur Respir J 1995; 8: 1388 ± 1420
8 BTS. Guidelines for the management of chronic obstructive pulmo−
nary disease. Thorax 1997; 52 (Suppl 5): S1 ± S28
9 Canadian Respiratory Review Panel. Guidelines for the treatment of
chronic obstructive pulmonary disease (COPD). Monograph, 1998
10 Laitinen L, Koskela K et al. Chronic bronchitis and chronic obstructive
pulmonary disease: Finnish national guidelines for prevention and
treatment 1998 ± 2007. Respir Med 1999; 93: 297± 332
11 Lorenz W, Ollenschläger G et al. Das Leitlinienmanual von AWMF und
ÄZQ. ZaeFQ 2001; 95 (Suppl. I): 41± 43
12 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesell−
schaften. Erarbeitung von Leitlinien für Diagnostik und Therapie.
Methodische Empfehlungen. Abrufbar unter: http://www.uni−dues−
seldorf.de/WWW/AWMF,
13 Society for Medical Decision Making. Committee on standardization
of clinical algoritms. Proposals for clinical algorithm standards. Med
Decis Making 1992; 12: 149± 154
14 Report of an expert committee: Definition and diagnosis of pulmo−
nary disease with special reference to chronic bronchitis and emphy−
sema. WHO Techn Rep Ser 1961; 213: 14± 19
15 Ciba guest symposium report: Terminology, definitions and classifi−
cations of chronic pulmonary emphysema and related conditions.
Thorax 1959; 14: 286 ± 299
16 Konietzko N, Fabel H. Weißbuch Lunge 2000. Stuttgart−New York:
Thieme,
17 Statistisches Bundesamt. Statistisches Jahrbuch, Jahrgänge
1968 ±1999. Stuttgart−Mainz: Kohlhammer,
18 Murray CJL, Lopez AD. The global burden of disease: A comprehensive
assessment of mortality and disability from diseases. Injuries and
risk factors in 1990 and projected to 2020. Cambridge: Harvard Uni−
versity Press, 1996
19 Lopez AD, Murray CJL. The global burden of disease, 1990 ±2020. Na−
ture Med 1998; 4: 1241± 1243
20 Nowak D, Berger K, Lioppert B et al. Epidemiology and health econo−
mics of COPD across Europe. A Critical Analysis. Treat Respir Med
2006; 4: 381± 395
21 Fabel H, Konietzko N (Hrsg). Weißbuch Lunge. Stuttgart, New York:
Thieme Verlag, 2005
22 Rulff LK, Volmer T, Nowak D. The economic inpact of smoking in Ger−
many. Eur Respir J 2000; 16: 385 ± 390
23 Rychlik R, Pfeil T, Daniel D et al. Zur sozioökonomischen Relevanz
akuter Exacerbationen der chronischen Bronchitis in der Bundesre−
publik Deutschland. Dtsch Med Wschr 2001; 126: 353± 359
24 Nowak D, Dietrich ES, Oberender P et al. Krankheitskosten von COPD
in Deutschland. Pneumologie 2004; 58 (12): 837 ± 844
25 Laurell CB, Eriksson S. The electrophoretic alpha−1 globulin pattern of
serum in alpha−1 antitrypsin deficiency. Scand J Clin Lab Invest
1963; 15: 132± 140
26 Orie NGM, Sluiter HJ, De Vreis K et al. Bronchitis, an international
symposium. Assen, Netherlands: Royal Vangorum, 1961: 43± 59
27 Svanes C, Omenaas E, Heuch JM et al. Birth characteristics and asthma
symptoms in young adults: results from a population−based cohort
study in Norway. Eur Respir J 1998; 12: 1366 ± 1370
28 Todisco T, de Benedictis FM, Iannacci L et al. Mild prematurity and re−
spiratory functions. Eur J Pediatr 1993; 152: 55± 58
29 Stein CE, Kumaran K, Fall CH et al. Relation of fetal growth to adult
lung function in South India. Thorax 1997; 52: 895 ± 899
30 Morgan WJ. Maternal smoking and infant lung function: further evi−
dence for an in utero effect. Am J Respir Crit Care Med 1998; 158:
689 ± 690
31 U.S. Surgeon General. The health consequences of smoking: chronic
obstructive pulmonary disease. Washington DC: U.S. Department of
health and human services, 1984. Publication No. 84±50205
32 Leuenberger P, Schwartz J, Ackermann−Liebrich U et al. Passive smok−
ing exposure in adults and chronic respiratory symptoms (SAPALDIA
Study). Swiss Study on air pollution and lung diseases in adults.
SAPALDIA Team. Am J Respir Crit Care Med 1994; 150: 1222 ± 1228
33 Dayal HH, Khuder S, Sharrar R et al. Passive smoking in obstructive
respiratory disease in an industrialized urban population. Environ
Res 1994; 65: 161± 171
34 Holt PG. Immune and inflammatory function in ciacutegarette smo−
kers. Thorax 1987; 42: 241 ± 249
35 Kauffmann F, Droulet D, Lellouch J et al. Twelve years spirometric
changes among Paris area workers. Int J Epidemiol 1979; 8: 201 ±212
36 Niewoehner DE. Anatomic and pathophysiological correlations in
COPD. In: Baum Gl, Crapo JD, Celli BR, Karlinsky JB (eds). Textbook
of pulmonary diseases. Philadelphia: Lippincott−Raven, 1998: 823 ±
842
37 Chen JC, Mannino MD. Worldwide epidemiology of chronic obstructi−
ve pulmonary disease. Current Opin Pulmon Med 1995; 5: 93± 99
38 Behera D, Jindal SK. Respiratory symptoms in Indian women using
domestic cooking fuels. Chest 1991; 100: 385 ± 388
39 Georgopoulos D, Anthonisen NR. Symptoms and signs of COPD. In:
Cherniack NS (ed). Chronic obstructive pulmonary disease Toronto:
Saunders, 1991: 357± 363
40 CriØe; C−P, Berdel D, Heise D et al. Empfehlungen der Deutschen
Atemwegsliga zur Spirometrie. Dustri−Verlag Dr. Karl Feistle, ISBN
3±87185±364−X),
41 Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung
function tests. Eur Respir J 2005; 26: 948± 968
42 Taube MD, Lehnigk B, Paasch K et al. Factor analysis of changes in
dyspnea and lung function parameters after bronchodilatation in
Vogelmeier C et al. Leitlinie der Deutschen Atemwegsliga ¼ Pneumologie 2007; 61: e1 ± e40